AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · United States

HB9559

IBOGAINE Act

Status

Pending

119th Congress

Still pending as of Oct 21, 2026: referred to the Subcommittee on Health on July 17, 2026.

IntroducedJun 30, 2026 (done)
PassedNext step (current)
Signed— (upcoming)
Law in effect— (upcoming)

Sponsor: Morgan Luttrell (Republican)
Type: Clinical Research
Substances: Multiple
Session dates: January 3, 2025 – January 3, 2027

Official text

Summary (from PoliPsy)

To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: congress.gov

Legislative history

July 17, 2026
Referred
July 17, 2026
Referred
June 30, 2026
Referred
June 30, 2026
Introduced

Loading bill…